Streamlining Acute Promyelocytic Leukemia Diagnosis: The Case for a Unified PML-RARA Testing Solution

Accurate molecular subtyping of leukemias is a cornerstone of precision oncology, shaping both therapeutic decisions and patient outcomes. Among acute myeloid leukemia (AML) subtypes, acute promyelocytic leukemia (APL) is both clinically urgent and therapeutically promising. Despite its aggressive presentation, APL is one of the most curable leukemias when diagnosis and treatment is initiated without delay. 

The diagnostic benchmark for APL is the detection of the PML-RARA gene fusion. Three breakpoint cluster regions in the PML gene—bcr1 (long isoform), bcr2 (variant isoform), and bcr3 (short isoform)—can fuse with the RARA gene to generate distinct fusion transcripts. The molecular assay used to detect these fusion transcripts at diagnosis can also be used to monitor for residual disease post-treatment, making it a critical test across the continuum of care.

Despite its clinical importance, PML-RARA detection is often fragmented and inefficient. Some conventional PML-RARA analysis workflows make it difficult to test for all three gene fusions quickly and efficiently. While the treatment for APL is similar regardless of the isoform, clinical laboratories must test for all three to confirm the diagnosis. Currently, many laboratories have to purchase separate kits for each gene fusion, requiring multiple kits, reagents, and runs per patient sample. 

Staffing shortages and rising healthcare costs make improving workflow efficiency increasingly important. However, laboratory teams may be reluctant to develop an in-house assay for all three gene fusions given the rarity of the PML-RARA subtype, which accounts for no more than 15 percent of AML cases.

A single, multiplexed assay capable of detecting all PML-RARA isoforms in one reaction could help address these workflow challenges. Ideally, such an assay would be highly sensitive, compatible with common qPCR platforms, and designed to run under the same conditions as more commonly performed molecular tests—such as BCR-ABL1 testing for chronic myeloid leukemia—so it could be integrated into existing workflows without substantial modifications or staff retraining. Automated analysis tools could further enhance efficiency and help standardize reporting, as well as support faster turnaround times.

Clinical laboratory teams continue to face increasing workloads alongside persistent staffing shortages and cost-saving measures. Within this context, AML subtyping through PML-RARA tests illustrates how consolidating rare but critical assays may reduce complexity and costs, streamline workflows, and help accelerate diagnosis. Collaboration between clinical laboratories and diagnostic developers will be essential in advancing solutions that benefit both labs and patient care.